Key Highlights:
| Aspect | Details |
|---|---|
| Drug Approved | Pimavanserin (34 mg capsule) |
| Therapeutic Use | Treatment of hallucinations and delusions in Parkinson’s disease psychosis |
| Global Market | Sold under the brand NUPLAZID®, a preferred treatment in the US antipsychotic segment |
| Projected Sales (2025) | Acadia Pharmaceuticals expects NUPLAZID® and DAYBUE™ to generate over $1 billion in net sales |
| Indian Market Strategy | Offers extended to Indian pharma companies for local distribution. |
| Company Expertise | Manufacturing APIs, intermediates, formulations & nutraceuticals |
Management Commentary
"The approval marks a major milestone for Bajaj Healthcare," said Anil Jain, Managing Director of Bajaj Healthcare Limited. "The success of NUPLAZID® in the US underscores the global demand for this innovative therapy. We are confident that its introduction in India will be a transformative advancement in the antipsychotic segment. This move further solidifies our presence in the CNS (Central Nervous System) market and reflects our commitment to advancing healthcare solutions in India."The company reassured that its strong manufacturing capabilities will ensure that API and final drug formulations meet international quality standards.
Regulatory & Market Impact
- Stock Trading Update: The company reaffirmed that the trading window for its securities remains closed for directors and designated employees in line with insider trading regulations.
- Global Expansion: Bajaj Healthcare has an established presence in Europe, the USA, Australia, the Middle East, and South America, positioning itself as an international pharmaceutical player.
